At the 8-week study midpoint, 9 of 10 participants had decreased IFN scores relative to baseline, except participant AA2 who reported a COVID-19 vaccination three days prior to the visit and was pausing tofacitinib at the time of the blood draw (Figure 6 – figure supplement 1a). The gene discussed is IFNA1; the disease is COVID-19.